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Key Points
• About half of the muta-
tions other than KIT
D816V identified in SM
patients were germline
in nature.
• Somatic EZH2 gene
mutations provide
prognostic information
in addition to that of
the well-established
S/A/R gene panel.
Systemic mastocytosis (SM) is a highly heterogeneous disease with indolent and aggressive
forms, with the mechanisms leading to malignant transformation still remaining to be
elucidated. Here, we investigated the presence and frequency of genetic variants in 34 SM
patients withmultilineal KIT D816V mutations. Initial screening was performed by targeted
sequencing of 410 genes in DNA extracted from purified bone marrow cells and hair
from 12 patients with nonadvanced SM and 8 patients with advanced SM, followed by
whole-genome sequencing (WGS) in 4 cases. Somatic mutations were further investigated in
another 14 patients with advanced SM. Despite the fact that no common mutation other
than KIT D816V was found in WGS analyses, targeted next-generation sequencing identified
67 nonsynonymous genetic variants involving 39 genes. Half of the mutations were somatic
(mostly multilineal), whereas the other half were germline variants. The presence of $1
multilineal somatic mutation involving genes other than KIT D816V, $3 germline
variants, and $1 multilineal mutation in the SRSF2, ASXL1, RUNX1, and/or EZH2 genes
(S/A/R/E genes), in addition to skin lesions, splenomegaly, thrombocytopenia, low
hemoglobin levels, and increased alkaline phosphatase and b2-microglobulin serum levels,
were associated with a poorer patient outcome. However, the presence of $1 multilineal
mutation, particularly involving S/A/R/E genes, was the only independent predictor for
progression-free survival and overall survival in our cohort.
Introduction
Systemic mastocytosis (SM) comprises a heterogeneous group of hematological disorders that is
characterized by the accumulation of abnormal mast cells (MCs) in multiple tissues that usually include
the skin and bone marrow (BM).1 According to the World Health Organization (WHO) criteria,2,3 most
SM patients (.90%) have indolent SM (ISM) and a normal life expectancy4-6; however, a fraction of the
patients might present with (or progress to) advanced forms of the disease, such as aggressive SM
(ASM), SM associated with another hematological neoplasm (SM-AHN), and, less frequently, MC
leukemia (MCL).3-5,7 The mechanisms leading to malignant transformation of SM remain to be fully
elucidated.
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The KIT D816V somatic mutation is present in the majority of adult
SM patients,8,9 particularly among ISM and ASM cases.10 Thus,
although this KITmutation might represent the genetic driver of SM,
on its own it cannot explain malignant transformation of the disease.
However, multilineal involvement of BM hematopoiesis by the
KIT D816V mutation, found in approximately one third of ISM cases
and the great majority of advanced forms of SM,6,10,11 particularly
when this mutation is already present in an early pluripotent
precursor cell also involving mesenchymal stem cells (MSCs),
significantly enhances the probability of progression from ISM to
advanced forms of SM.12 Altogether, these findings suggest
that acquisition of additional genetic alterations along with the
KIT mutation and/or the existence of a specific genetic background
might be required for progression of ISM to more severe forms of
the disease.13-15 Hence, recent studies based on relatively limited
gene panels have shown that advanced forms of SM, including 177
of 284 SM-AHN cases, 28 of 284 ASM cases, and 8 of 284 MCL
cases,13,15-18 often carry mutations in genes previously reported
to be altered in other myeloid neoplasms,19-21 in addition to the
KITmutation. However, relatively limited information exists about the
frequency of mutations in those genes in diagnostic subtypes of
SM other than SM-AHN (eg, ISM and smoldering SM [SSM] in
addition to ASM and MCL). Also, these mutations have been found
in the other hematological neoplasm component of the disease but
not in the MC compartment.22,23 In addition, it remains unknown
whether the occurrence of such mutations in an early hematopoietic
precursor would also confer a worse prognosis to SM patients, as
demonstrated by Jawhar et al for SM-AHN cases17 and previously
reported for KIT D816V.12
Here, we first investigated the presence and frequency of genetic
variants, for a total of 410 genes, on purified BM MCs, maturing
neutrophils, and T cells (plus hair in cases with multilineal gene
involvement) from 20 SM patients presenting with a multilineal
KIT D816V mutation, followed by whole genome sequencing
(WGS) in 4 cases. In a second step, the somatic mutations
identified were investigated in whole BM samples from another 14
advanced SM patients. To define the clonal hierarchy of the genetic
variants identified, patients’ genomic (g)DNA obtained from
different (purified) BM cell populations and hair was sequenced
in parallel. Then the number and type of nonsynonymous (coding)
genetic variants identified were compared among the distinct
diagnostic subtypes of SM and related to patient outcome. Our
results show, for the first time, a high frequency of germline
mutations in advanced SM, in addition to the previously described
somatic mutations, most of which were also found to involve
multiple hematopoietic cell lineages. Somatic EZH2 gene mutations
provide prognostic information, in addition to that of the well-
established SRSF2, ASXL1, and/or RUNX1 (S/A/R) gene panel,
in our series of SM patients.
Materials and methods
Patients
Overall, 34 patients (15 females and 19 males), 12 with non-
advanced SM but high-risk features (ie, ISM with multilineal
involvement by the KIT D816V mutation and high serum baseline
tryptase levels) and 22 with advanced forms of SM (ie, 4 SSM,
11 ASM, and 7 SM-AHN), diagnosed at the reference center
(Virgen del Valle Hospital) of the Spanish Network on Mastocytosis
(REMA) were studied (median age at diagnosis, 52 years; range,
0-76 years) based on (1) the presence of multilineal KIT D816V
mutation, including involvement of MSCs in every ISM case tested,
(2) high (.100 mg/L) tryptase serum levels, and (3) follow-up time
from diagnosis$ 1 year (median, 6.5 years; range, 1-48). In an initial
series (test series) of 20 patients (12 nonadvanced and 8 advanced
SM cases; patients 1-20 in Table 1) sufficient ($5 3 104) highly
purified BM MCs, maturing neutrophils, and T cells were also
required to perform further molecular analyses. In all 20 patients,
hair was collected in parallel with the purified BM cell populations.
In the additional 14 advanced SM cases (cases 21-34 in Table 1),
availability of a whole BM sample was required to enter the study.
Diagnosis and classification of SM were reviewed based on
2016 WHO criteria.2 All patients showed BM MC aggregates in
histology with CD251 KIT D816V mutated and cytologically altered
BM MCs; in addition, median serum baseline tryptase levels at
diagnosis in nonadvanced and advanced SM cases were 268.5mg/L
(range, 115-1298) and 224mg/L (range, 112-1469), respectively. To
detect SM-AHN, conventional WHO cytomorphology and immuno-
phenotypic criteria,2 based on the EuroFlow ALOT and acute myeloid
leukemia (AML)/myelodysplastic syndrome (MDS) antibody panels,24
were used, respectively; at diagnosis, no patient showed BM
infiltration by blast cells or other cells (in the absence of pathological
MCs) compatible with a non-MC myeloid malignancy. Information
about patient treatment is available in supplemental Table 7. Prior to
entering the study, each individual gave his/her written informed
consent to participate according to the Declaration of Helsinki, and
the study was approved by the local institutional Ethics Committees.
During the study period, 20 of 34 patients showed disease
progression or died from SM-related causes, whereas the remaining
14 cases had stable disease (Table 1), after a median follow-up from
initial diagnosis of 6.5 years. Briefly, 9 ISM cases progressed to SSM
(n 5 3) or ASM (n 5 6), 8 ASM patients showed progression to
ASM-AHN (n 5 6) or died from SM-related causes (n 5 2), and 3
SM-AHN patients died from SM-related causes. None of the patients
showed progression to MCL, and none of the 34 SM patients had a
history of familial mastocytosis.
Purification of BM cell populations
Identification and isolation of antibody-stained (supplemental Table 1)
BM MCs, maturing neutrophils, T cells, and MSC populations were
performed in the initial cohort of 20 patients, as described in
supplemental Methods, using well-established stain-and-then-lyse-
and-wash procedures10 and a 4-way fluorescence-activated cell
sorter (FACSAria III) equipped with FACSDiva software (both from
BD, San Jose, CA), as described elsewhere.10,25 The purity of the
FACS-sorted cells was systematically.98%, in the absence of cross-
contamination by MCs (,0.001%) or any other KIT D816V1 BM cell
population.
Analysis of the KIT D816V mutation
Positivity for the KIT D816V mutation was assessed in gDNA of
FACS-purified BM MCs, maturing neutrophils, T cells, and MSCs
using a quantitative real-time allele-specific oligonucleotide PCR
method, as described.26,27
Targeted gDNA sequencing
Overall, 40 ng of gDNA from purified BM MCs and maturing
neutrophils was used for targeted sequencing of all exons of 409
genes in a first cohort of 20 cases (patients 1-20 in Table 1). For this
purpose, the AmpliSeq Comprehensive Cancer Panel was analyzed
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on an Ion Proton platform (both from Life Technologies, Carlsbad,
CA), according to the manufacturer’s instructions. Only those
nonsynonymous coding genetic variants identified based on the
GRCh37 reference genome28 with $1003 allele coverage were
selected.
Subsequently, the following additional filters were applied to
discriminate between acquired genetic variants (ie, somatic
mutations) and germline mutations vs genetic variants present in
the Spanish population (ie, single nucleotide polymorphisms). First,
the above results were compared with the 5000 exomes,29 the IBS
1000 Genome Project,30 and the ExAC31 population databases.
Then, only those genetic variants that had not been previously
reported in Spanish and/or in European (non-Finnish) populations
and/or those with a minor allele frequency,0.001 were considered
in this study. Subsequently, the exome of 36 control gDNA samples
representative of the Spanish healthy population (Spanish National
DNA Bank Carlos III, University of Salamanca, Salamanca, Spain;
http://www.bancoadn.org), pooled into 3 groups of 12 individuals
per group, was sequenced to discriminate between the actual
genetic variants found in SM patients and technical sequencing
artifacts. Then, potentially deleterious mutations, as defined by the
SIFT32 and PolyPhen33 algorithms, were selected and confirmed by
Sanger sequencing on gDNA extracted from purified BM MCs,
neutrophils, and T lymphocytes. Finally, the somatic vs germline
nature of the genetic variants was evaluated by Sanger sequencing
of gDNA obtained from paired patient’s hair. Germline mutations
were defined as those gene variants detected in gDNA from hair
with an allele frequency;50%. In 1 patient (case 9 in Table 1), the
germline nature (vs early acquisition of the mutation during
embryonic development) could be tested (and confirmed) in
gDNA from his mother’s hair. Additionally, the SRSF2-p.P9534
mutational hotspot was investigated through Sanger sequencing
of BM-derived gDNA from all 20 patients.
The new mutations identified were classified according to their
pattern of distribution in different cell compartments, as follows: (1)
hematopoietic (acquired) somatic mutations either restricted to
MCs or (2) shared by MCs and other myeloid and/or lymphoid cells
(ie, multilineal mutations) and (3) inherited rare germline variants or
mutations acquired early during embryonic development, when the
genetic variant was also present in gDNA from hair (supplemental
Table 2).
Based on the somatic mutations found, a customized library for
target sequencing of 15 genes (ie, ASXL1, CDH11, DNMT3A,
EPHA7, EZH2, ICK, IKZF1, ITGA10, KAT6B, PIK3CD, ROS1,
RUNX1, SF3B1, SRSF2, and TET2) was designed and analyzed in
an additional cohort of 14 advanced SM patients (4 SSM, 3 ASM
and 7 SM-AHN; patients 21-34 in Table 1). A total of 200 ng of BM
gDNA per patient was used to prepare DNA libraries with a TruSeq
Custom Amplicon Low Input kit (Illumina, San Diego, CA) and
sequenced at 2 3 150-bp read length on an Illumina HiSeq 2500
genome sequencer, following the manufacturer’s instructions.
WGS
gDNA from purified BM MCs and T lymphocytes from patients 9, 10,
13, and 14was used to generate a single short-insert library. Libraries
were sequenced on an Illumina HiSeq 2500 instrument to generate
paired-end 2 3 100-bp reads at a minimum of 110 G of data per
sample (average coverage of 48.4 total reads; range, 41.9-53.9). The
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aligned to the GRCh37/hg19 reference sequence28 according to
GATK best practices.35 Bulk read statistics were calculated using
samtools36 (version 1.3.1, stats subcommand). Exon coverage was
calculated using bedtools37 (version 2.26.0, coverage subcommand)
with exon ranges from UCSC Known Genes38 downloaded with the
UCSC Table Browser.39 Only those genetic variants with $203
allele coverage were considered. Sequencing metrics for each
specimen are provided in supplemental Table 3.
Statistical analyses
The Kruskal-Wallis and Mann-Whitney U tests were used to
assess the statistical significance (set at P , .05) of differences
observed among groups. Overall survival (OS; calculated from the
time of diagnosis to death or the last follow-up visit) and progression-
free survival (PFS; calculated from the time of diagnosis to disease
progression/death or the last follow-up visit in case of stable disease)
curves were plotted according to the Kaplan-Meier method and
compared using the Breslow (ie, generalized Wilcoxon) test, as
suggested by Bouliotis and Billingham40 for data with a nonpropor-
tional hazard pattern. Receiver operating characteristic curve analysis
was used to identify the most sensitive cutoff for the number of
genetic variants that discriminated between patients with distinct OS
and PFS. For multivariate analyses, the covariate adjustment model41
was applied to those variables found to be statistically different in
the univariate analysis, and the Cox proportional hazard regression
model was then used. SPSS software (SPSS version 20.0; IBM
Corporation, Armonk, NY) was used for all statistical analyses.
Results
Nonsynonymous coding genetic variants identified in
SM patients
In addition to KIT D816V, targeted next-generation sequencing (NGS)
analyses of purified BM cell populations obtained from the first cohort
of 20 SM patients showed 37 583 genetic variants (median: 1347 per
case; range: 662-2431) that resulted in 52 nonsynonymous coding
genetic variants involving 39 genes, after excluding population allele
filters and technical artifacts (supplemental Table 2). Only 10 of 39
genes (ASXL1, DCC, DNMT3A, EZH2, IKZF1, LRP1B, RUNX1,
SF3B1, SRSF2, and TET2) were recurrently mutated (ie, present in
$2 patients) (supplemental Table 2). Interestingly, 46% (24/52) of the
nonsynonymous coding genetic variants found are reported here for
the first time (supplemental Table 2).
Fifteen of the 39 mutated genes harbored half of the genetic
variants detected (26/52), which were confirmed to be somatic
mutations present in hematopoietic cells but absent in hair gDNA; in
contrast, the remaining 24 mutated genes carried germline genetic
variants (or early acquired mutations), because they were present at
;50% allele burden in all hematopoietic cells tested and in the
patients’ hair (supplemental Table 2). Of note, the germline nature
of the IGF2R mutation in patient 9 was confirmed in gDNA
extracted from his mother’s hair. Also, most somatic mutations
(20/26, 77%) corresponded to multilineal mutations that involved
myeloid (17/26, 65%) or myeloid plus lymphoid (3/26, 12%)
hematopoietic BM cells, in addition to MCs, and only a few
mutations (6/26, 23%) were restricted to the MC compartment in
BM (supplemental Table 2).
Subsequent WGS analysis of BM MCs and T cells from 4 ASM
cases showed a genome-wide mutation frequency of between
0.008 and 0.19 mutations per megabase (Mb; average of 0.12
mutations per Mb) (Table 2). After applying filters to discriminate
for MC-specific genetic variants (supplemental Methods), only 10
nonsynonymous coding or canonical splice site MC-specific variants
(range: 0-4 per case) were found (supplemental Table 5). Only 1 of
10 MC-specific genetic variants identified in the PIK3CD gene by
WGS analysis was also screened by targeted NGS. Interestingly,
similar allele burdens were found, despite the distinct sequencing
methods used (ie, 33% for WGS and 37% for targeted NGS).
Ten of the 14 advanced SM patients included in the second patient
cohort (71%) harbored a total of 15 mutations, other than KIT
D816V, involving 9 genes, of which 2 (RUNX1, SRSF2) were
recurrently mutated. Interestingly, 5 of these 15 mutations (33%)
were reported here for the first time (supplemental Table 3).
Clonal hierarchy of somatic mutations involving
hematopoietic cells
All 20 patients screened for mutations within purified BM cell
populations showed multilineal involvement of BM hematopoietic
cells by KITD816V, and KITD816V–mutated MSCs were detected
in 11 of 13 cases tested, including 9 of 9 ISM cases (patients 2, 3,
5, 6, 7, 9, 10, 11, and 12) and 2 of 4 ASM cases (patients 13 and
14). Also, targeted NGS analyses showed that 11 of 20 patients
carried additional mutations.
Detailed analysis of the mutated allele burden within the MC
population and the different hematopoietic cell lineages involved
(supplemental Table 2) revealed heterogeneous patterns of distribu-
tion of somatic mutations in hematopoietic cells. Briefly, KIT D816V
apparently emerged as the first somatic mutation acquired by
hematopoietic cells in 4 of 11 cases: patients 5 (ISM), 14 (ASM),
17 (ASM), and 18 (ASM) (supplemental Figure 1A). In 1 ISM
patient (patient 7) who had KIT and RUNX1 mutations, the KIT
mutation was associated with a greater degree of involvement of
hematopoiesis (including KIT D816V–mutated MSCs), pointing out
its potential emergence at an earlier stage than the RUNX1
mutation; however, lower percentages of mutated MCs for KIT vs
RUNX1 (24% vs 50% allele burden, respectively) were observed,
which may indicate that the 2 mutations might had been acquired in
different clones/subclones, in the absence of chromosomal/genetic
gains and/or losses (supplemental Figure 1B). Likewise, a pattern
consistent with the coexistence of 2 different clones/subclones was
found in 2 other ASM cases (patients 19 and 20) that progressed to
ASM-AHN (supplemental Figure 1B). Of note, in patient 19, AML
blasts identified at progression tested positive for the EZH2
mutation but lacked KIT D816V. In turn, in another ASM case
Table 2. Number and type of genetic variants identified in purified
BM MCs from SM patients by WGS (n 5 4)
Patient ID SNVs Indels
Total variants
(SNVs 1 indels) Mutations per Mb
9 15 7 22 0.008
10 486 15 501 0.18
13 534 21 555 0.19
14 267 9 276 0.10
Average 326 13 339 0.12
Indels, insertions and deletions; SNV, single nucleotide variant.
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(patient 16) that progressed to ASM-AHN, KIT D816V was a
secondary event to the TET2 mutation (supplemental Figure 1C).
Finally, in 2 ISM cases (patients 11 and 12) and 1 ASM case
(patient 15), the precise clonal hierarchy could not be defined with
the available data.
Mutational profiles in ISM vs ASM
A higher median number of nonsynonymous coding genetic variants
per patient was detected in ASM (median, 3 mutations per case;
range, 1-11 mutations per case) compared with ISM (median, 1
mutation per case; range, 0-4 mutations per case; P 5 .02)
(Table 3). Likewise, similar differences were also found when we
restricted the analysis to the number of somatic mutations that
involved multiple BM hematopoietic cell lineages (Table 3): 3 of 12
ISM cases (25%) vs 7 of 8 ASM cases (88%) (P 5 .008). In
contrast, similar numbers of somatic mutations restricted to the MC
compartment in the BM and of germline mutations/variants were
observed in ISM vs ASM patients (Table 3).
Impact of the mutational profile on the outcome
of SM
Receiver operating characteristic curve analysis showed that the
presence of $3 genetic variants in genes other than KIT was
the most sensitive cutoff for discriminating between patients
with distinct OS and PFS. Thus, SM patients who carried $3
nonsynonymous coding genetic variants other than KIT D816V
showed a significantly shortened PFS (median: 3 vs 30 years) and
OS (median: 6 years vs not reached) compared with patients with
,3 mutations (P 5 .002 and P , .001, respectively) (Figure 1A).
Similarly, the presence of$3 germline variants was also associated
with a shorter PFS (median, 3 vs 14 years) and OS (median, 4 years
vs not reached) compared with cases with ,3 germline variants
(P 5 .016 and P 5 .004, respectively) (Figure 1B), whereas the
presence of$1 somatic mutation (other than KIT D816V) involving
multiple hematopoietic cell lineages showed an adverse impact on
PFS (median, 3 vs 30 years) and OS (median: 6 years vs not
reached) compared with the absence of somatic mutations other
than KIT D816V (P5 .009 and P5 .001, respectively) (Figure 1C).
In contrast, the presence of somatic mutations (other than KIT
D816V) restricted to the MC compartment showed no prognostic
impact on PFS or on OS of SM patients (Figure 1D).
Interestingly, when we restricted the analysis to those mutations
involving the SRSF2, ASXL1 and/or RUNX1 (S/A/R) gene panel2,17
among all 34 SM patients, a significant impact on PFS and OS
(P , .001 and P 5 .002, respectively) was also observed (Table 4;
Figure 2A). Interestingly, the status of the EZH2 gene (ie, the most
frequently mutated gene among our patients) in S/A/R-negative
patients further identified, amongS/A/R-nonmutated cases, 2 patient
groups with distinct outcomes (Figure 2B). Hence, $1 mutation in
the new SRSF2, ASXL1, RUNX1, and/or EZH2 (S/A/R/E) gene
panel showed an increased significant impact on PFS (P, .001) and
OS (P, .001) vsS/A/R genes alone (Table 4; Figure 2C). Moreover,
increased alkaline phosphatase serum levels (P 5 .01), thrombocy-
topenia (P 5 .03), and splenomegaly (P 5 .04) showed an impact
on patients’ PFS (Table 4). In turn, the presence of skin lesions
(P5 .02), thrombocytopenia (P5 .04), decreased hemoglobin levels
(P 5 .001), and increased alkaline phosphatase (P 5 .01) and b2-
microglobulin serum levels (P5 .04) at diagnosis were all significantly
associated with a shorter OS in the univariate analysis (Table 4).
Multivariate analysis of prognostic factors, for the 20 SM patients in
whom the somatic vs germline nature of the mutations identified was
assessed, including those variables that had a significant impact on
patient outcome in the univariate analysis (alkaline phosphatase
serum levels and the number of multilineal, somatic, and total
[somatic plus germline] mutations, for PFS, and the former variables
plus platelet counts and the number of germline genetic variants, for
OS), showed that the presence of $1 somatic mutation (other than
KIT D816V) with multilineal hematopoietic involvement was the only
independent predictor for PFS (P 5 .003; hazard ratio [HR], 2.8;
95% confidence interval [CI], 1.4-5.5) and OS (P 5 .002; HR, 9.3;
95% CI, 2.2-39.2). In turn, multivariate analysis of prognostic factors
based on those variables with a significant impact in the univariate
analysis that were available in all 34 SM patients studied (ie, alkaline
phosphatase serum levels, platelet count, splenomegaly, and pres-
ence of S/A/R or S/AR/E gene mutations, for PFS, and these
variables plus skin lesions and hemoglobin and b2-microglobulin
serum levels, for OS) showed that the presence of S/A/R/E gene
mutations (HR, 7.6; 95%CI, 2.2-26; P5 .001 for PFS and HR, 13.1;
95% CI, 2.7-64; P 5 .001 for OS) was the only independent
predictor for a worse patient outcome (Table 5).
Discussion
Despite the (potentially) early acquisition of the KITD816V mutation
during ontogeny,12 the onset of clinical symptoms associated with
advanced forms of SM often occurs at middle or late adulthood.5,42
Such observations suggest that continuous activation of the
defective (ie, D816V-mutated) SCF/KIT pathway in an early
progenitor cell does not confer a malignant phenotype per se,
whereas it might facilitate malignant transformation of the disease,
either because of an increased susceptibility to acquire secondary
“oncogenic” mutations and/or by cooperating with a particular
(preexisting) genetic background. Thus, results derived from murine
models43,44 and SM patients13,42,43 indicate that coexistence of
different mutations along with KIT D816V is required for the
development of advanced SM. Hence, recent studies have found
higher numbers of additional (somatic) mutations in advanced SM
vs ISM patients.13 Despite these observations, neither additional
somatic mutations (apart from KIT D816V) nor a specific genetic
background have been reported in common among advanced SM
cases.13,16-18,34,43,45-47
This is the first study in which a large number of genes that might be
involved in malignant transformation of nonadvanced to advanced
forms of SM have been investigated in a group of SM patients
presenting with multilineal KIT D816V mutation and high serum
tryptase levels. For this purpose, the complete coding regions of
410 genes (including the SRSF2 p.P95 hotspot) were first analyzed
in gDNA from purified BM cell populations from 20 SM patients.
Despite the fact that progression of ISM to more aggressive forms of
the disease is a relatively rare event,2 a high rate of progression was
observed within our ISM cases; this high rate of progression could be
explained by the patient-selection criteria (advanced SM patients plus
nonadvanced ISM cases with high-risk features, such as high serum
tryptase levels and multilineal involvement of the hematopoiesis by
the KIT D816V mutation,6 including, in the great majority of cases, KIT
D816V–mutated BM MSCs12) and the long follow-up of our cases.
Overall, no common mutation shared among ASM and ISM cases
that showed disease progression was found. Hence, except for the
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Figure 1. Kaplan-Meier estimates of PFS
and OS of SM patients (n 5 20) grouped
according to the number and type of
mutations detected. Panels describe PFS
(left panels) and OS (right panels) of patients
grouped according to the number of total
genetic variants (A), germline genetic variants
(B), multilineal somatic mutations (C), and MC
restricted (somatic) mutations (D). Values are
expressed in years from diagnosis to disease
progression (PFS) and death (OS) or the last
follow-up visit. Median PFS and/or OS indicates
the time point at which half of the patients have
progressed to more aggressive forms of the
disease or died, respectively.
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Table 4. SM patients: prognostic factors for PFS and OS (n 5 34)
Disease features n
Univariate analysis
PFS, y OS, y
Median (range) P Median (range) P
Clinical and laboratory features
Diagnosis
Nonadvanced SM 12 14 (2-32) NS NR (3-48) NS
Advanced SM 22 11 (1-18) 11 (1-18)
Age at diagnosis, y
,60 23 14 (1-32) NS NR (1-48) NS
$60 11 5 (1-10) 6 (1-12)
Skin lesions
No 10 4 (1-6) NS 6 (1-13) 0.02
Yes 24 14 (1-32) NR (3-48)
BM MCs, %
,1 14 5 (1-19) NS 11 (1-19) NS
$1 18 14 (1-32) NR (1-48)
sBT, mg/L
,200 10 15 (1-17) NS NR (1-17) NS
$200 22 6 (1-32) NR (1-48)
Hemoglobin, g/L
,100 5 3 (1-6) NS 4 (1-7) .001
$100 29 14 (1-32) NR (1-48)
Platelets, 3109/L
,100 11 4 (1-15) .03 4 (1-17) .04
$100 23 14 (1-32) NR (1-48)
b2-microglobulin, mg/mL
,2.5 7 NR (2-18) NS NR (3-17) .04
$2.5 20 5 (1-32) 10 (1-48)
SAP, U/L
,150 16 32 (2-32) .01 NR (3-48) .01
$150 14 4 (1-30) 10 (1-39)
Splenomegaly
No 11 30 (1-30) .04 NR (1-39) NS
Yes 23 5 (1-32) 11 (1-48)
Hepatomegaly
No 16 15 (1-19) NS NR (1-19) NS
Yes 18 5 (1-32) 11 (1-48)
Number of nonsynonymous coding genetic variants
Total somatic mutations
0 9 30 (2-32) .02 NR (3-48) .005
$1 11 4 (1-15) 6 (2-17)
MC restricted
0 15 14 (1-32) NS NR (2-48) NS
$1 5 6 (1-15) 7 (6-17)
Multilineal
0 10 30 (2-32) .009 NR (3-48) .001
$1 10 3 (1-10) 6 (2-10)
NR, not reached; NS, not statistically significant (P . .05); SAP, serum alkaline phosphatase; WT, wild-type.
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IKZF1 p.N159S, RUNX1 p.R162K, and SRSF2 p.P95R mutations
found in 2 patients each, all other (specific) genetic variants identified
were detected in our series in a single case. In line with this as well,
only 2 of 67 variants (SF3B1 p.K666T and SRSF2 p.P95R
mutations) identified in this study had been reported in SM patients.16
Furthermore, WGS performed in a subset of 4 ASM patients (ie,
ASM without an another hematological neoplasm [AHN]), confirmed
the absence of common nonsynonymous (coding) genetic variants,
other than KIT D816V. Interestingly, the mutation rate observed
within purified BM clonal MCs in these 4 cases (0.12 per Mb) was
significantly lower than that reported for other myeloid neoplasms48
and other types of cancer.49 Such a reduced overall mutational rate
of ASM cases could be due to the lower genetic/genomic instability
of advanced SM compared with other myeloid malignancies;
however, despite the fact that the number of BM MCs is typically
increased in ASM vs ISM, the most relevant “tumor” cell in advanced
SM patients might be hematopoietic precursor cells10,50 and not
pathological BM MCs, because all of these cases had multilineal
involvement of the hematopoiesis by KIT D816V. If this holds true,
neutrophils and, to a lesser extent, T cells would probably share most
of the genetic variants found in pathological MCs. In line with this
hypothesis, our results confirmed that most (77%) somatic mutations
identified in BM MCs were also present in the myeloid or the myeloid
plus lymphoid BM cells analyzed.
Surprisingly, half of all genetic variants found in BM MCs were also
detected in gDNA from paired hair samples at;50% allele burden,
suggesting that they would correspond to germline genetic events
or to mutations acquired early during ontogeny. Interestingly, most
patients (70%) carried$1 (potentially deleterious) germline genetic
event for the 410 genes investigated in this study, which reveals an
extremely high frequency compared with the 4% to 30% cases with
germline mutations identified in pediatric and adult populations with
other types of cancers.51-53 Despite this, the presence of germline
mutations only showed a prognostic impact for PFS and OS when
$3 germline variants were present in the same patient. However, all
3 cases displaying $3 germline variants (patients 18, 19, and 20)
also carried a greater number of additional (multilineal) somatic
mutations, identifying a potential greater genomic instability among
these patients. This might also explain the greater and independent
prognostic impact of the number of somatic vs germline mutations
among our patients. Despite all of the above, the small number of
cases analyzed here and the lack of uniform criteria across different
laboratories to label a germline mutation as a deleterious variant,54
including the use of different filtering criteria for their identification,
patients with germline mutations in cancer-related genes are being
identified more frequently and, due to their distinct clinical behavior,
they now represent a unique subtype of myeloid malignancies in the
current WHO classification.3
Recently, age-related clonal hematopoiesis (ARCH) has been
associated with somatic mutations in genes also found to be altered
frequently in myeloid neoplasms (eg, the ASXL1, DNMT3A, EZH2,
RUNX1, SF3B1, SRSF2, and TET2 genes) involving ;10%
of otherwise healthy individuals by the age of 70 years.55,56 Of
note, these individuals would have a 12-fold higher relative risk for
developing a hematological cancer; therefore, ARCH is considered
an age-related preleukemic condition.57,58 In line with this finding,
half of our SM patients who harbored$1 ARCHmutation (n5 10/18
cases; 56%) already exhibited an AHN at diagnosis or subsequently
developed an AHN in addition to the SM, whereas these mutations
affected a smaller percentage of SSM (11%) and ASM (33%) cases.
These findings might suggest that acquisition of ARCH-associated
gene mutations in ISM patients could be a trigger for a (myeloid)
AHN, but not progression to SSM or ASM.
Analysis of the potential sequence of acquisition of somatic mutations
in multimutated patients (coexistence of $2 somatic mutations)
showed a potentially early acquisition of the KIT mutation in
approximately one third of cases. In another third of our cases, the
KIT D816V mutation emerged in a distinct clone or later than
other multilineal somatic mutations involving, for example, the TET2,




PFS, y OS, y
Median (range) P Median (range) P
Germline genetic variants
,3 17 14 (1-32) .016 NR (4-48) .004
$3 3 3 (1-4) 4 (2-10)
Total genetic variants
,3 11 30 (2-32) .002 NR (3-48) ,.001
$3 9 3 (1-6) 6 (2-10)
Gene panel mutational status
S/A/R
WT 23 15 (2-32) ,.001 NR (3-48) .002
Mutated 11 2 (1-4) 6 (1-13)
S/A/R/E
WT 19 30 (2-32) ,.001 NR (3-48) ,.001
Mutated 15 3 (1-6) 6 (1-13)
NR, not reached; NS, not statistically significant (P . .05); SAP, serum alkaline phosphatase; WT, wild-type.
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developing SM-AHN. Altogether, these findings support previous
observations in (mostly) SM-AHN patients that showed a pre-
dominance of gene mutations, other than KIT D816V alone or in
combination with KIT mutations, in (in vitro) expanded colony-forming
cells from SM patients.16 Moreover, in the only case in which we could
confirm that the KIT mutation was a secondary genetic event, the
development of a myeloid proliferative neoplasm occurred just prior to
death. The apparent discrepancy between our data and previous data
indicating that the KIT mutation might frequently occur as a distinct
and late event16 in advanced mastocytosis might be due to the fact
that all multimutated patients analyzed in such series (12/12)
corresponded to SM-AHN patients16 with preferential growth of KIT
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Figure 2. Kaplan-Meier estimates of PFS and OS of SM patients (n 5 34) grouped according to the mutational status of SRSF2, ASXL1, RUNX1 and EZH2
genes. PFS (left panels) and OS (right panels) of SM patients grouped according to the presence vs absence of mutated S/A/R genes (A), the EZH2 mutational status within the
S/A/R gene panel (B), and the presence vs absence of mutated S/A/R/E genes (C). Values are expressed in years from diagnosis to disease progression (PFS) and death (OS) or
the last follow-up visit. Median PFS and/or OS indicates the time point at which half of the patients have progressed to more aggressive forms of the disease or died, respectively.
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wild-type vs KIT-mutated tumor cell precursors, whereas our series
was selectively enriched for multilineal KIT-mutated ISM and ASM
cases. However, clonogenic assays and/or single-cell analyses have
not been performed in this study; therefore, our conclusions should be
viewed with caution.
Interestingly, among our cases, most genes targeted by acquired
somatic mutations, other than KIT D816V (ie, ASLXL1, DNMT3A,
EZH2, IKZF1, RUNX1, SF3B1, SRSF2, TET2), had previously been
found to be mutated in advanced SM13,16,17,34,46,47 and/or in other
myeloid neoplasias,19,21,45,55,59-62 and their multilineal nature was
shown in this study for the first time. In addition, the number of mutated
genes (apart from KIT) with multilineal involvement of hematopoiesis
increased significantly from ISM to ASM cases, in line with previous
observations.17 Altogether, these findings further support the role of
the KIT D816V mutation as a trigger for advanced SM under a
“dangerous” genetic background, defined not only by the (number of)
preexisting germline variants, as well as by the presence of (previously)
acquired multilineal mutations in genes other than KIT. Actually, the
presence of $1 somatic mutation with multilineal hematopoietic
involvement, in addition to KIT, or the presence of$3 nonsynonymous
coding genetic variants (including somatic and germline events) in the
genes investigated in this study significantly increased the probability of
progression of SM and of shortening the OS of SM patients.19,20,60
To explore the potential clinical utility of NGS screening based on a
reduced number of genes, we investigated the prognostic impact of
the previously reported (adverse) S/A/R gene panel17 in our patients.
Our results confirmed that patients carrying $1 mutation in S/A/R
genes had significantly poorer PFS and OS.17 However, inclusion of
EZH2 into a S/A/R/E gene panel revealed that the combination of
mutations in these 4 genes had greater predictive value for PFS
and OS than did the well-established S/A/R gene panel, because
S/A/R/E gene mutations were shown to be the only independent
predictor for PFS andOS in our SMpatients. Of note, EZH2was 1 of
the most frequently mutated genes in our series and 1 of the most
frequently mutated genes in other cohorts of patients with SM13,16
and other myeloid neoplasms,19,20,63 where its mutations emerged as
never being shared with SRSF2 mutations64,65; this might contribute
to explain its additional prognostic information over the S/A/R gene
mutations. This observation differs from data reported by other
investigators17,62 who also tested the influence of mutations in the
EZH2 gene; however, both studies17,62 included a significantly shorter
median patient follow-up than ours (eg, 3.6 and 2 years vs 6.5 years,
respectively), a period during which less than half of our ISM patients
who progressed would have transformed to SSM and other forms of
advanced SM. Thus, further investigations in larger series of SM
patients, with a long follow-up, are required to confirm these findings.
In summary, our results show that no individual genetic lesion apart
from the (multilineal) KIT mutation appears to be an independent
predictor for malignant transformation of SM; however, progression
of ISM to more advanced forms of the disease most likely requires
an altered multimutated genetic background of both (KIT-mutated)
tumor MCs and other hematopoietic BM cells. Germline and
multilineal somatic mutations (particularly those involving the SRSF2,
ASXL1, and RUNX1 genes in addition to the EZH2 gene) emerge
as critical genetic markers associated with disease progression
and a shortened OS for ISM patients at higher risk of disease
progression.
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